TP53 and ovarian cancer: Support on this finding was provided by Yan et al., in which a significantly lower intracellular accumulation and DNA binding of cisplatin and carboplatin was detected in ANXA3 overexpressing ovarian cancer cells, accompanied by a decrement of the intracellular p53 level (Yan et al., 2010).